By labeling CTCs with other specific surface antibodies, such as the human epidermal growth factor receptor 2 (HER-2) in the case of breast cancer (see section “Isolation of CTCs from patients”), or even with an antibody cocktail, the probability to capture EpCAM negative cells will increase. Here, ERBB2 is linked to breast cancer.